Leerink analyst Jason Gerberry lowered his price target for Allergan (AGN) to $357 ahead of the company's updated 2015 guidance, which he expects to be announced next week. The updated outlook will exclude Allergan's generics business, which it sold to Teva (TEVA). Gerberry expects the new Allergan to post 2016 earnings per share of $17.01 on sales of $18.4B, and 2017 earnings of $20.04 on sales of $20.1B. He forecasts top- and bottom-line five-year compounded annual growth rates for Allergan of 6% and 11%, respectively. The new company's growth will be driven by new product pipeline, growth brands and operating leverage, Gerberry tells investors in a research note. He keeps an Outperform rating on the stock.